Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It looks like it is halted pending news, like ACBFF is also....more to come. IMO GLTA
This is a daily anomaly. GWPH is even worse. Never buy or sell at market for these weed stocks. NAME YOUR PRICE !
What was with the insane swing today? Huge movement up then slammed back down again. Did it have to do with shorts closing positions cause that was a serious run up. Kinda curious if anyone has an explanation for this.
Gl long here
Looks like there was some after hours or pre-market activity. Quite a few shares for this stock (192,000). Average trading volume for 10 days is 103,000.Somebody knows something ?
Canada's parliament had a meeting 4/30. The transcript isn't out yet (in a few weeks) but that is the only catalyst I can see. It will go back down. We are months away from any law.
Because Ihubbers like drama.
This stock has a lot of potential. Wonder why there are not many posts on it.
This stock has a lot of potential. Wonder why there are not many posts on it.
This stock has a lot of potential. Wonder why there are not many posts on it.
Though this was very personal to me, I'm sure it's not the first or last. We need to push for new laws.
very sorry, half the system feeds you opiates the other treats you like a dope head and wouldn't give you Advil without suspicion. I work in the medical field and its sad in many aspects.
Very sad news. Sorry for your loss.
I have some sad news I feel I need to share - hopefully it will fall on the right ears. A very good and close friend of mine was in a car accident about 10 years ago. Without going into a lot of detail, he was in tremendous pain from that point on. He was enrolled in a pain management program for the last few years. They periodically did blood work and found CBD in his system. He explained that he started using it recently to try and stop his pain. They said if he continued using it, he would be kicked out of the program, so he stopped. Last Sunday morning, he hung himself in his basement.
I am more than pissed. I'm sad, angry and heartbroken that are medical treatment system is so FUCKED UP!
Peace. Hug your loved ones today.
Some good news out the last few days.
This is a very promising stock but seems to be overlooked by investors. I have done real well so far on a thousand shares.
nice week, and nobody here. Guess there's not enough drama for the IHubbers.
"Foreign companies, mostly Canadian, positioning themselves as exporters to Germany are the clear winners of this decision, according to executives and analysts."
https://mjbizdaily.com/german-court-hits-brakes-medical-cannabis-license-plan/
Better Marijuana Stock: MedReleaf vs. Organigram Holdings
Keith Speights, The Motley Fool
Keith Speights, The Motley Fool
Motley FoolMarch 29, 2018
Last year, both MedReleaf (NASDAQOTH: MEDFF) and Organigram Holdings (NASDAQOTH: OGRMF) boasted tremendous stock performances. MedReleaf's share price soared nearly 150%, while Organigram gained close to 90%. It's been a different story so far in 2018, though, with MedReleaf stock down nearly 20%, and Organigram basically flat for the year.
But the future prospects for these Canadian marijuana growers are much more important to investors than past performance. Which of these two marijuana stocks is the better pick now? Here are the strongest arguments for buying MedReleaf and for buying Organigram Holdings.
Marijuana growing in greenhouse
Marijuana growing in greenhouse
Image source: Getty Images.
The case for MedReleaf
Why consider buying MedReleaf stock? There are three primary reasons. First, the company claims a solid share of the expanding medical marijuana market in Canada. Second, MedReleaf is in position to increase its presence in the even larger global medical marijuana market. And third, the company looks forward to a tremendous growth opportunity with pending legalization of recreational marijuana in Canada.
On the first point, MedReleaf currently has around 17% of the Canadian market for dried cannabis. Extracts such as cannabidiol (CBD) make up a little over one-fifth of MedReleaf's total revenue, but the products are generating the most sales growth for the company.
The Canadian medical marijuana market could more than triple in size by 2024 to $1.3 billion annually. MedReleaf could possibly make in the ballpark of $250 million per year solely from medical cannabis sold domestically. That represents sales potential roughly 5.5 times the company's current level of sales, based on annualizing its latest quarterly results.
But the global medical marijuana market presents an even greater opportunity for MedReleaf. London-based Prohibition Partners projected that the European medical marijuana market could be worth $42.8 billion annually. That projection assumes that more European countries will legalize medical marijuana, but it highlights the potential. Even conservative estimates using only countries that currently allow medical marijuana reflect an opportunity several times the size of Canada's medical marijuana market.
MedReleaf is definitely angling for its place in this global medical marijuana market. The company recently announced an agreement to become the largest supplier of medical cannabis to Cannamedical Pharma GMBH, a leading medical cannabis distributor to pharmacies in Germany.
Then there's the recreational marijuana market in Canada. Although recreational cannabis use isn't legal yet in the country, the Canadian senate recently voted to allow a bill that would legalize the drug for recreational purposes to be reviewed by committees. Assuming the legislation is approved as expected, Canada's legal recreational marijuana market will open for business by September 2018.
The Canadian Parliamentary Budget Officer (PBO) projects this market to be between $4.2 billion and $6.2 billion annually. Others think it could be even higher than that. If MedReleaf can capture a market similar to what it has for dried medical cannabis, the company could be looking at additional sales of up to $1 billion per year.
Canadian red maple leaf cutout next to marijuana buds and a pack of marijuana cigarettes
Canadian red maple leaf cutout next to marijuana buds and a pack of marijuana cigarettes
Image source: Getty Images.
The case for Organigram
Investors have similar reasons to consider buying Organigram stock. Like MedReleaf, Organigram is already an active player in the Canadian medical marijuana market. Although it's smaller than MedReleaf, the company has made a name for itself. Organigram won two out of six product category awards at the 2017 Canadian Cannabis Awards.
Organigram clearly has its sights set on the Canadian recreational marijuana market as well. The marijuana grower has been busy expanding its production capacity in anticipation of recreational cannabis legalization in Canada. Organigram will have 227,500 square feet of production space when all of its building projects are completed.
The company has already signed supply agreements with two provinces for the adult recreational marijuana market. These two deals combined represent a minimum of 6,000 kilograms per year, which translates to a retail value between $48 million and $72 million.
What about the global medical marijuana market? Organigram hasn't been a major player in Germany or other markets outside of Canada yet. However, the company formed a new international division and recently hired Guillermo Delmonte to run the unit. Delmonte was previously CEO of ICC Labs, the first South American cannabis company to go public. Organigram plans to target medical marijuana markets in Europe, Australia, and in other regions across the world.
Perhaps the most compelling reason to buy Organigram is its valuation. That might sound ridiculous, considering that the stock currently trades at nearly 84 times sales. However, the massive growth prospects for Organigram using some estimates could give the stock a price-to-earnings-to-growth (PEG) ratio of close to 0.52. If the growth estimates are even close to being accurate, Organigram is arguably a bargain for growth-oriented investors.
Better buy
In my view, choosing between marijuana stocks comes down to how much production capacity you can get for the money. Using that as a guideline, MedReleaf has the advantage over Organigram.
Even though MedReleaf stock has performed poorly so far this year, I suspect that it will rebound as the date for legalization of recreational marijuana in Canada approaches. Of course, this should cause Organigram stock to jump also.
Aside from its greater production capacity, MedReleaf also has a leg up when it comes to going after the international market. The deal with Cannimedical should help the company as it attempts to catch up with rivals that already have their foot in the door in Germany.
While I think that MedReleaf is the better buy between these two, keep in mind that investing in marijuana stocks is a risky proposition. Their prospects rely entirely on sales growth meeting expectations. And despite the excitement, marijuana is still a commodity. Both the medical and recreational marijuana markets will therefore inevitably become commoditized. But I suspect that will happen later rather than sooner -- which should bode well for MedReleaf's near-term prospects.
A good read on why PPS is down compared to other Big MMJ companies.
Why MEDFF Stock is Tanking Despite Big German Move
https://www.profitconfidential.com/stock/medreleaf-stock/medff-stock-germany-expansion/
Agreed ! Sit and wait.
nice and slow is good for MedReleaf, me thinks. The key is to get established before the US and the rest of the World figures out how much MONEY is being made in Canada
Germany has several suppliers. Still good, since MEDFF is certified. Time will tell. Laws change.
this is a good thing otherwise they would grow their own.
This program is not as liberal as those in the United States and Canada.
In Germany, medication will only be accessible to patients suffering from a small group of serious conditions such as cancer, glaucoma, HIV/AIDS, Hepatitis C and Parkinson's diseases to name a few.
Germans must also receive a recommendation from a doctor that indicates cannabis is a last resort.
However - despite these initial limitations - this new legislation is a big win for Germany's cannabis market and cannabis investors.
•Medical cannabis will now be sold in pharmacies.
•It will be covered by insurance.
•As the program evolves, restrictions will loosen, and more conditions will be added.
Germany's medical program sets the stage for a recreational program. We see this cycle play out in Canada right now.
http://www.ino.com/blog/2017/09/3-cannabis-stocks-profiting-germanys-new-medical-program/#.Wq_78cty7IU
I dont think people realize how big this news is that was released today...
MedReleaf signs supply agreement with Cannamedical Pharma GmbH in Germany
https://www.newswire.ca/news-releases/medreleaf-signs-supply-agreement-with-cannamedical-pharma-gmbh-in-germany-677247523.html
The population of Germany is 86 Million, while Canada's population sits at 36 million.
When the Canadian Shoppers drug mart news came out, this thing ran up to $25.00 PPS
People will start realizing it soon imo
MEDFF
very good news!! shows management is working to grow and gain brand recognition.
This is good news, MedReleaf has exclusive rights to the "Woodstock" brand.
https://www.newswire.ca/news-releases/medreleaf-adds-the-iconic-woodstock-brand-to-its-recreational-market-portfolio-675971383.html
Todays news was probably already posted but here it is again.
I hold no position at this time.
$$$$$$$$$$$$$$MEDFF$$$$$$$$$$$$$
https://finance.yahoo.com/news/better-marijuana-stock-medreleaf-vs-151600294.html
This seems to be the only mmj stock that shows any positive move lately.
We saw about 16 per cent revenue growth, quarter over quarter, and volume has continued to grow, as it has always after each quarter since our inception,” says Closner. “MedReleaf has been profitable almost since our first year of operation. We like to say we’ve generated more profits in this industry than all the other licensed producers in the country combined.”
https://www.cantechletter.com/2018/02/medreleaf-ceo-we-have-been-more-profitable-than-all-other-lps-combined/
MEDFF
Thanks for the update
Big news just out about an hour ago, still under the radar...
Quebec selects MedReleaf as recreational cannabis supplier
Quebec has entered into a multiyear agreement with at least one licensed producer to lock up marijuana supply for the province’s retail and online recreational stores, according to a regulatory filing released Tuesday.
Ontario-based MedReleaf disclosed it has signed a letter of intent with Société des alcools du Quebec (SAQ) to supply 8,000 kilograms of cannabis products per year over a three-year term. Financial terms were not disclosed.
The SAQ is a Montreal-based liquor distributor, but it created a subsidiary, Société des cannabis du Quebec, to handle marijuana distribution.
With adult-use legalization in Canada looming late this summer, the province is the largest market to start securing a cannabis supply so far.
Aggregate demand in Quebec is estimated to be roughly 100,000 kilograms (220,462 pounds) annually, but the regulated market is expected to take a number of years to overtake black-market sales.
https://mjbizdaily.com/quebec-selects-medreleaf-recreational-cannabis-supplier/
MedReleaf Reports Third Quarter Fiscal 2018 Results
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/13/MedReleaf-Reports-Third-Quarter-Fiscal-2018-Results
MARKHAM, ON, Feb. 13, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF)(OTC:MEDFF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced financial and operating results for the third quarter fiscal 2018 ending December 31, 2017. All amounts expressed are in Canadian dollars unless otherwise noted.
"In the third quarter, we set new records for total sales and grams sold demonstrating the strength of our underlying business while we continue to make investments in preparation for the recreational market and for international expansion," said Neil Closner, CEO of MedReleaf. "These investments are starting to bear fruit and we now have boots on the ground in six different countries working on various initiatives – both for cultivation and export. We also launched our first adult recreational-use brand, San Rafael '71, which is getting good reception from the various Provincial purchase authorities. With a strong balance sheet bolstered by $192.5 million in equity capital raised since last December, we have a clear opportunity to establish MedReleaf as a global leader in the cannabis industry."
REST OF RELEASE: https://www.dailymarijuanaobserver.com/single-post/2018/02/13/MedReleaf-Reports-Third-Quarter-Fiscal-2018-Results
"In the third quarter, we set new records for total sales and grams sold demonstrating the strength of our underlying business while we continue to make investments in preparation for the recreational market and for international expansion," said Neil Closner, CEO of MedReleaf. "These investments are starting to bear fruit and we now have boots on the ground in six different countries working on various initiatives – both for cultivation and export. We also launched our first adult recreational-use brand, San Rafael '71, which is getting good reception from the various Provincial purchase authorities. With a strong balance sheet bolstered by $192.5 million in equity capital raised since last December, we have a clear opportunity to establish MedReleaf as a global leader in the cannabis industry."
MedReleaf Reports Third Quarter Fiscal 2018 Results MEDFF
MARKHAM, ON, Feb. 13, 2018 /CNW/ - MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced financial and operating results for the third quarter fiscal 2018 ending December 31, 2017. All amounts expressed are in Canadian dollars unless otherwise noted.
"In the third quarter, we set new records for total sales and grams sold demonstrating the strength of our underlying business while we continue to make investments in preparation for the recreational market and for international expansion," said Neil Closner, CEO of MedReleaf. "These investments are starting to bear fruit and we now have boots on the ground in six different countries working on various initiatives – both for cultivation and export. We also launched our first adult recreational-use brand, San Rafael '71, which is getting good reception from the various Provincial purchase authorities. With a strong balance sheet bolstered by $192.5 million in equity capital raised since last December, we have a clear opportunity to establish MedReleaf as a global leader in the cannabis industry."
Third Quarter Fiscal 2018 Financial Highlights
•Record sales of $11.4 million, an increase of 9% from the prior year period, and a 16% increase from the second quarter of fiscal 2018.
•Sold a record 1,263 kilograms of cannabis products, an increase of 27% from the prior year period and a 20% increase from the second quarter of fiscal 2018.
•Sales of cannabis-based extract products were $2.3 million, or 21% of total sales.
•Adjusted EBITDA loss of $0.2 million, a decrease of $4.3 million from the prior year period due to discounts offered to qualifying Veterans as a result of the Veterans Affairs Canada (VAC) reimbursement policy change, overhead costs associated with the Bradford Facility construction, and operating investments towards future growth.
•Average selling price per gram of $8.98, a decrease from $10.50 for the prior year period due to the reduction in VAC reimbursement pricing.
•Cash cost per gram sold of $1.83, an increase from $1.55 for the prior year period primarily due to increased plant operating costs and fixed overhead attributable to the Bradford Facility. Cash cost per total gram sold is expected to improve as greater efficiencies of scale are realized when construction of the Bradford Facility is fully completed.
•Adjusted product contribution margin per gram sold of $5.80, a decrease from $8.65 for the prior year period.
Third Quarter Fiscal 2018 Business Highlights
•On November 14, 2017, MedReleaf's Australian join venture partner, Indica Industries Pty Ltd. (t/a "MedReleaf Australia"), was granted a licence from the Australian Government Office of Drug Control ("ODC") for the cultivation and production of medical cannabis.
•On November 30, 2017, MedReleaf won 10 awards at the 2017 Lift Canadian Cannabis Awards including Top Licensed Producer and first place product awards for: Top Indica Flower, Top High CBD Flower, Top High THC Flower, and Top High CBD Oil.
•On December 4, 2017, the Company closed a bought deal equity financing for gross proceeds of approximately $60.0 million.
•On December 21, 2017, the Company announced an agreement to become a medical cannabis supplier to Shoppers Drug Mart.
https://www.newswire.ca/news-releases/medreleaf-reports-third-quarter-fiscal-2018-results-673897783.html
MedReleaf's San Rafael '71 Launches With Cannabis-inspired Beer
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/09/MedReleafs-San-Rafael-71-Launches-With-Cannabis-inspired-Beer
MARKHAM, ON, Feb. 9, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced the introduction of its first adult-use recreational brand: San Rafael '71, inspired by and designed to celebrate the spirit of classic cannabis culture.
San Rafael '71 has been designed with the classic consumer in mind, one of the largest segments of the Canadian cannabis market. San Rafael '71 is for adults who are discerning and knowledgeable about cannabis products and those who value quality and an authentic experience.
To mark the launch and to introduce Canada to the brand, the company has partnered with one of Canada's most well-regarded brewers, Amsterdam Brewing, to develop and launch the first San Rafael '71 product, 4:20 Pale Ale.
"While cannabis aficionados eagerly anticipate the day they can buy legal products, we thought we'd offer the San Rafael '71 4:20 Pale Ale for them to enjoy while they wait," noted Darren Karasiuk, VP Strategy at MedReleaf. "San Rafael '71 4:20 Pale Ale does not contain any cannabis, but it will take you back to where it all began and introduce Canadians to the spirit of adventure, exploration and freedom at the heart of 4:20."
4:20 began as a reference to the time of day when a group of friends would meet to search for what was believed to be a hidden crop of cannabis. The meeting place was San Rafael, California and the year was 1971. Over the past half century, 4:20 has evolved to more broadly symbolize cannabis folklore and lifestyle. MedReleaf brought these historical facts together to develop a new brand – San Rafael '71 – that genuinely captures and celebrates the spirit of the classic cannabis culture.
"Our award-winning team created a flavour profile using a unique blend of citrus and summit hops and specialty malts that gives a nod to the cannabis experience with peach and pine aromas giving way to spice and mild bitterness," noted Jeff Carefoote, CEO of Amsterdam Brewing. "In a further nod to 4:20, San Rafael '71 4:20 Pale Ale contains 4.20% alcohol by volume and 42 IBUs."
San Rafael '71 4:20 Pale Ale will be available in 473ml cans at The Beer Store starting February 12th, and is currently in Amsterdam's two retail locations and on tap in more than 40 of the GTA's finest establishments.
"4:20 is a defining symbol of cannabis culture, and we wanted to celebrate and pay tribute to that history and inspiration," noted Neil Closner, CEO of MedReleaf. "As we have said before, MedReleaf intends to fortify and extend its leadership position in the industry beyond the medical market. The launch of San Rafael '71 is the first of many steps on this front including a portfolio of brands and products that leverage the company's award-winning product selection, quality and innovation."
A full suite of San Rafael '71 products and experiences will be introduced to the marketplace as regulations allow.
We encourage adults interested in keeping up to date on brand and product developments to visit www.sanrafael71.com and provide their email address. Enthusiasts can follow along on social as well @sanrafael71.
About MedReleaf Corp.
Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 90001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer.
MEDFF News! MedReleaf introduces first adult-use recreational cannabis brand: San Rafael '71 launches with cannabis-inspired beer
MARKHAM, ON, Feb. 9, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced the introduction of its first adult-use recreational brand: San Rafael '71, inspired by and designed to celebrate the spirit of classic cannabis culture.
San Rafael '71 has been designed with the classic consumer in mind, one of the largest segments of the Canadian cannabis market. San Rafael '71 is for adults who are discerning and knowledgeable about cannabis products and those who value quality and an authentic experience.
To mark the launch and to introduce Canada to the brand, the company has partnered with one of Canada's most well-regarded brewers, Amsterdam Brewing, to develop and launch the first San Rafael '71 product, 4:20 Pale Ale.
"While cannabis aficionados eagerly anticipate the day they can buy legal products, we thought we'd offer the San Rafael '71 4:20 Pale Ale for them to enjoy while they wait," noted Darren Karasiuk, VP Strategy at MedReleaf. "San Rafael '71 4:20 Pale Ale does not contain any cannabis, but it will take you back to where it all began and introduce Canadians to the spirit of adventure, exploration and freedom at the heart of 4:20."
More at...
https://www.newswire.ca/news-releases/medreleaf-introduces-first-adult-use-recreational-cannabis-brand-san-rafael-71-launches-with-cannabis-inspired-beer-673553683.html
Here is another new one in Canada that went public April 2017
problem is its OTC gray in the US
weedMD
Looks attractive for a good move the next couple days.
Probably because its not a penny stock lol
MEDFF
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
161
|
Created
|
06/26/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |